neurocare group

What neurocare group does

neurocare group AG is a Munich/Ilmenau-based private medical technology company founded in 2015 that operates a vertically integrated platform for personalized mental health treatment. The company combines proprietary hardware (including the FDA-cleared Apollo TMS Therapy System, TMS neuronavigation, neurofeedback systems, EEG/QEEG devices, and tDCS/tES stimulators) with its Digital Therapy Platform, which integrates brain mapping, sleep analysis, and AI to support personalized therapy protocols across its own and partner clinics. The platform targets treatment-resistant depression, OCD, ADHD, insomnia, and anxiety through non-invasive neuromodulation.

The company monetizes through five revenue streams: hardware sales (TMS devices and accessories to clinics globally), managed clinic services (20+ owned clinics across Germany, Netherlands, UK/Ireland, US, and Australia), professional training through the neurocare Academy (online and in-person courses), software platform licensing (Digital Therapy Platform to third-party clinics), and market-entry sales enabled by regional regulatory approvals (notably Saudi Arabia following May 2026 SFDA approval). Sub-brands include Apollo TMS, neurocare Academy, QEEG Labs, and acquired entities MAG & More, Smart TMS, MeJa Psychologie, and neuroConn devices.

Strategic activity in 2024-2026 has accelerated: EUR 35.3 million raised across rounds led by TVM Capital Healthcare with Impact Expansion; acquisitions of Smart TMS (UK/Ireland, 9 clinics) and MeJa Psychologie (Netherlands, expanding to 11 clinics); multiple FDA clearances (adolescent depression, OCD, iTBS protocol); Japan patent grant and Kyowa joint venture; MDMA approval in Saudi Arabia; and 2026 partnerships with NRx Pharmaceuticals, Zeta Surgical, and Emobot Health extending into integrated drug-device therapy, robotic TMS, and AI depression monitoring. The company maintains ISO 9001 certification for Netherlands clinic operations and holds a planned public listing as a stated objective.

Name

neurocare group

Legal name

neurocare group AG

Website

https://neurocaregroup.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

neurocare group AG is a German-based medical technology company that delivers personalized mental health treatment via a proprietary Digital Therapy Platform combining neuromodulation hardware (TMS, neurofeedback, tDCS) with AI-enabled brain mapping and sleep analysis, serving patients and clinics across Germany, Netherlands, UK/Ireland, US, Australia, and MENA.

Ownership category

akta.pro rank

Product category

Neuromodulation & Mental Health Technology

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Neurology Telemedicine Platforms (HLALAGAC), General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA)

Keywords

• Transcranial magnetic stimulation
• Neuromodulation therapy devices
• Personalized mental health care
• Digital therapy platform
• Clinical neurofeedback systems

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Hardware Sales (TMS Devices): Sale of medical devices including Apollo TMS systems, TMS neuronavigation, tDCS/tES devices, neurofeedback systems, and EEG/QEEG equipment to clinics and healthcare providers globally.
2. Clinic Services: Operation of owned clinics providing neuromodulation therapies (TMS, neurofeedback, tDCS) and psychotherapy to patients with mental health conditions. Revenue from treatment sessions across owned clinic network in Germany, Netherlands, Australia, US, UK, and Ireland.
3. Training & Academy Services: Professional education and training services for healthcare professionals including TMS courses, neurofeedback workshops, and tDCS training through online LMS platform and in-person workshops worldwide.
4. Software Platform Licensing: Licensing of Digital Therapy Platform to third-party clinics for personalized treatment management and quality assurance in mental health delivery.
5. International Expansion & Market Entry: MDMA approval obtained for TMS device sales in Saudi Arabia, enabling market entry into MENA region. Strategic expansion through partnerships and regulatory approvals in new geographic markets.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

neurocare group provides personalized mental health care through an integrated best-practice platform combining proprietary AI-powered Digital Therapy Platform with FDA-cleared neuromodulation hardware (TMS, tDCS/tES, neurofeedback, EEG/QEEG) and a global network of operated and partner clinics. The company sells TMS therapy systems and software platform licenses to third-party clinics and hospitals while also delivering treatment services directly to patients through its own clinics across Germany, the US, Australia, the Netherlands, the UK, and Ireland.

Product overview

neurocare group offers a unified best practice platform for personalized mental health care, combining proprietary hardware devices, software, and clinical services. The core offering includes the Digital Therapy Platform (DTP), which integrates AI, brain mapping, and sleep analysis for personalized treatment. The hardware portfolio spans TMS Systems (Apollo TMS Therapy), TMS Neuronavigation, tES & tDCS Devices, Neurofeedback Systems, EEG & QEEG Systems, and Actigraphy Devices. The company operates a global network of clinics (Germany, US, Australia, Netherlands, UK, Ireland) and offers professional training through neurocare Academy. The platform is supported by acquired brands including MAG & More and neuroConn devices, with recent expansion through Smart TMS Clinics acquisition.

Differentiator

Problem solved

Functional benefit

Brands

• Apollo TMS: TMS therapy devices that have received FDA clearance for depression, OCD, and adolescent major depression treatment
• Digital Therapy Platform (DTP)
• neurocare Academy
• QEEG Labs
• Neuronavigation

Products and services

• Digital Therapy Platform (DTP) Integrated software platform that empowers clinicians to embed leading therapy innovations, combining AI, brain mapping, and sleep analysis to support personalized mental health treatment. Deployed in neurocare's own and third-party clinics worldwide.
• Apollo TMS Therapy System FDA-cleared Transcranial Magnetic Stimulation (TMS) device for treatment of depression, OCD, and adolescent major depressive disorder. Features industry-leading iTBS (intermittent Theta Burst Stimulation) protocol.
• TMS Systems Systems for Transcranial Magnetic Stimulation applied in clinical and research settings, including Apollo TMS device and accessories for treating mental health conditions.
• TMS Neuronavigation Systems Leading neuronavigation systems for advanced practice and research of Transcranial Magnetic Stimulation, enabling precise targeting during TMS procedures.
• tES & tDCS Devices Stimulators for clinical practice and research in tDCS (transcranial Direct Current Stimulation), tACS (transcranial Alternating Current Stimulation), and tRNS (transcranial Random Noise Stimulation), compatible with advanced EEG and neuroimaging.
• Neurofeedback Systems Neurofeedback systems with optional biofeedback extensions and precision artefact control, used for conditions including ADHD, insomnia, and other neurological conditions.
• EEG & QEEG Systems Electroencephalogram (EEG) technology, purpose-built and compatible with neuromodulation modalities for practice and research, including brain mapping and quantitative EEG analysis capabilities.
• Actigraphy Devices Sleep hygiene assessment devices for patient care and research, used to monitor sleep patterns and support personalized treatment planning.
• neurocare Academy Professional training platform offering online and hands-on courses in TMS, neurofeedback, and tDCS for healthcare professionals worldwide.
• neurocare Clinics Global network of best practice clinics providing personalized mental health treatments using TMS, neurofeedback, tDCS, and psychotherapy across Germany, US, Australia, Netherlands, UK, and Ireland.

Quantifiable outcome

• 90% response rate and 70% remission rate in ONE-D Trial for accelerated TMS protocol (preliminary study)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, strategic and minor.

• NRx PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2026Joint offering launching nationwide program integrating TMS, medications, and psychotherapy to treat Depression, PTSD, and other mental health conditions. Combines neurocare's TMS technology with NRx's pharmaceutical pipeline.
• Zeta SurgicalstrategicTechnology or Integration · 1 January 2026Strategic partnership for robotic-enabled TMS technology development and integration.
• Smart TMScoreStrategic or Co-development Partner · 1 July 2024Acquired Smart TMS clinics (UK's largest TMS provider with 9 clinics) enabling expansion into UK and Ireland markets and integration of Digital Therapy Platform into UK clinics. Rebranded to neurocare in April 2025.
• MeJa PsychologiecoreStrategic or Co-development Partner · 1 January 2024Perinatal mental health specialists acquired to expand neurocare's Netherlands clinic network to 11 locations and mark key step into pregnancy/postpartum mental health care.
• Stimit AGminorStrategic or Co-development Partner · 1 August 2022Strategic cooperation with Stimit AG, a company developing solutions for neuromodulation and neuroplasticity enhancement.
• MAG & MorecoreStrategic or Co-development Partner · 1 May 2022German-based leader of Transcranial Magnetic Stimulation devices joined forces with neurocare group, combining MAG & More's TMS expertise with neurocare's platform approach.
• Fondazione Policlinico GemellistrategicStrategic or Co-development Partner · 1 January 2022Strategic cooperation in Rome to deliver neuromodulation treatments, expanding neurocare's European footprint.
• KyowastrategicStrategic or Co-development Partner · 1 January 2022Equity participation agreement paving the way for strategic joint venture in Japan, supporting neurocare's Japan market entry following patent grant.
• Mid-Ohio Behavioral HealthstrategicStrategic or Co-development Partner · 1 January 2022Collaborative arrangement expanding neurocare US footprint through partnership with Midwest behavioral health provider.

Scale indicators10 records

Recent moves11 records

Expansion highlights7 records

Broad incumbents

• Pear Therapeutics: Digital therapeutics company developing prescription software-based treatments for mental health conditions including depression. Overlaps with neurocare's Digital Therapy Platform approach to mental health delivery.
• Saluda Medical: Medical device company developing neuromodulation technologies for chronic pain and other conditions. Broader incumbent in the neuromodulation space with overlap in neurostimulation expertise.

Direct peers

• Brainsway: Israel-based medical device company that develops and markets Deep TMS systems for treatment of depression, OCD, and other neurological disorders. Direct competitor in TMS technology with FDA-cleared systems.
• Neuronetics: Commercial-stage medical technology company focused on designing, developing, and marketing TMS products (NeuroStar) for psychiatric and neurological disorders. Most direct competitor to neurocare's Apollo TMS in the treatment-resistant depression market.
• Sooma: Finland-based medical device company developing tDCS (transcranial Direct Current Stimulation) devices for depression and other neurological conditions. Direct competitor in the tDCS modality that neurocare offers.
• Flow Neuroscience: Sweden-based company offering a direct-to-consumer TMS device for depression treatment combined with behavioral therapy. Competes with neurocare in the personalized mental health neuromodulation space.
• Magstim: UK-based manufacturer of TMS stimulators and coils used in research, clinical, and neurosurgical applications. Competes with neurocare in the TMS hardware market globally.
• Greenbrook TMS: US-based operator of TMS treatment centers for major depressive disorder and other mental health conditions. Direct competitor to neurocare's clinic services business model in North America.

Emerging players

• eNeura: Developer of non-invasive neuromodulation devices (single-pulse TMS) for migraine treatment. Adjacent to neurocare in the non-invasive neuromodulation device category.
• Mindstrong Health: Digital mental health platform using AI and biomarkers to monitor and treat mental health conditions. Overlaps with neurocare's AI-enabled Digital Therapy Platform approach to mental health personalization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/@neurocaregroup
• YouTubeyoutube.com/@neurocaregroup
• Facebookfacebook.com/neurocaregroup
• LinkedInlinkedin.com/company/neurocaregroup
• Instagraminstagram.com/neurocaregroup

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about neurocare group